Status:
COMPLETED
Pramipexole Conversion to Ropinirole Controlled Release (CR)
Lead Sponsor:
Rajesh Pahwa, MD
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related t...
Detailed Description
Three different arms will be used in this study. Each of the three cohorts will be treated sequentially. Each participant will be taking Mirapex for PD and will be converted to Requip CR by 1 of 3 con...
Eligibility Criteria
Inclusion
- Diagnosis of Parkinson Disease
- Currently taking pramipexole
- Never have taken Requip CR
Exclusion
- Can not have significant adverse effects to standard Requip
- Can not have atypical PD due to drugs, metabolic disorders, encephalitis or degenerative diseases
- Can not have unstable medical conditions
- Can not be taking concurrent monoamine oxidase inhibitors except for selegiline (10mg per day or less)
- Female patients of childbearing potential must be using an effective method of contraception.
- Can not be pregnant or lactating.
- This may not be a complete list; there may be additional criteria which may apply.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00275275
Start Date
January 1 2006
End Date
May 1 2008
Last Update
August 24 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160